7 .alpha.-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7 .alpha.(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents

US6288051A · kind A · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Dieter Bittler · Berlin, DE
• Rolf Bohlmann · Berlin, DE
• Nikolaus Heinrich · Berlin, DE
• Jorg Kroll · Berlin, DE
• Gerhard Sauer · Berlin, DE
• Yukishige Nishino · Berlin, DE
• Karsten Parczyk · Berlin, DE
• Martin Schneider · Remchingen, DE
• Christa Hegelehartung · Berlin, DE
• Rosemarie Lichtner · Berlin, DE

Key dates

• Filing date: Oct 14, 1999
• Grant date: Sep 11, 2001
• Expiry date: Oct 14, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07J51/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This invention describes the new 7.alpha.-(5-methylaminopentyl)-estratrienes of general formula I ##STR1## in which PA1 R.sup.2 stands for a hydrogen or fluorine atom, PA1 R.sup.17 stands for a hydrogen atom, a methyl or ethinyl group, PA1 n stands for 2, 3 or 4, and PA1 x stands for 0, 1 or 2. The new compounds are strong, pure antiestrogens and can be used for the production of pharmaceutical agents for treatment of estrogen-dependent diseases, for example, breast cancer, endometrial carcinoma, prostatic hyperplasia, anovulatory infertility and melanoma.